Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate.
Bisphosphonates inhibit the development of experimental atherosclerosis and decrease the intima-media thickness of human carotid artery. Since arterial macrophages have a key role in atherogenesis, we studied whether clodronate, an antiatherogenic bisphosphonate, will suppress the appearance of macrophages generated by atheromatous process in the rabbit aorta. The atherosclerosis was caused in rabbits by means of a high-cholesterol (1%) diet, and the animals were treated simultaneously with saline (n = 11) or 25 mg/kg of clodronate disodium (n= 12) intravenously twice a week for 6 to 12 weeks. The cholesterol diet for 6 weeks caused no visible atheromatous plaques in the aorta, but feeding for 6 more weeks produced progressively atheromatous lesions. Immunohistochemistry with specific antimacrophage antibody showed an intensive accumulation of macrophages in the subendothelial layer of the aorta in cholesterol-fed rabbits treated with saline or clodronate for 6 weeks. In the aorta of rabbits treated with cholesterol diet + saline for 12 weeks, the area of immunoreactive macrophages extended from the internal elastic lamina up to the luminal surface of the aorta. However, far less immunoreactive macrophages were present in the atheromatous regions of the aorta of rabbits medicated with clodronate for 12 weeks; in the clodronate-treated animals the macrophages were located closer to the luminal surface of the aorta than in controls on saline. No atheromatous lesions and macrophages appeared in the aorta of rabbits on standard diet (n = 7). The results suggest that clodronate suppresses the appearance of cholesterol-phagocyting macrophages in arterial walls during atherogenesis.
Ylitalo
Ritva
R
Department of Pharmacological Sciences, University of Tampere, Medical School, Finland. ritva.ylitalo@santen.fi
Syvälä
Heimo
H
Tuohimaa
Pentti
P
Ylitalo
Pauli
P
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D001013:Aorta, Thoracic / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D001161:Arteriosclerosis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D002784:Cholesterol / Q000008:administration & dosage / Q000097:blood; D004002:Clodronic Acid / Q000494:pharmacology*; D004036:Diet, Atherogenic; D007150:Immunohistochemistry; D008264:Macrophages / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology; D008297:Male; D011817:Rabbits
D000963:Antimetabolites; D004002:Clodronic Acid; D002784:Cholesterol